CODETTA BIO

Codetta Bio operates in the biotechnology sector, specializing in multi-omics technology that provides quantitative and digital platforms for nucleic acid and protein assays. The company serves research and clinical customers, offering a comprehensive solution that allows for greater insights from a single sample. Codetta Bio's business model revolves around the development and commercialization of advanced multi-modal, multi-plex, and multi-omics platforms. These platforms are designed to deliver high sensitivity and simultaneous analyte detection, which are critical for both research and clinical applications. The company generates revenue through the sale of its proprietary technology and related services. Codetta Bio's market includes academic institutions, clinical research organizations, and pharmaceutical companies that require advanced tools for molecular analysis and diagnostics. The company is headquartered in Morrisville, North Carolina, with an R&D center in Durham, North Carolina. Key executives include TJ Johnson, Chief Executive Officer, and BJ Kerns, Chief Marketing Officer, both of whom bring extensive experience from previous roles in molecular diagnostics and biotechnology firms.

Keywords: multi-omics, biotechnology, nucleic acid, protein assays, quantitative platform, digital platform, clinical research, molecular analysis, diagnostics, high sensitivity.